10月21日，粤港澳大湾区国际脑机接口产业创新大会暨第六届脑科学前沿与产业大会在深圳光明区举行，会上发布《广东省脑机接口产业发展白皮书（2026版）》。白皮书显示，广东脑机接口产业已位居全国第一梯队，拥有脑机接口产品注册证或在研产品的重点企业超过100家，居全国首位；已登记脑机接口相关临床研究27项，占全国20.1%，28家医疗机构设立或筹建脑机接口临床研究病房，几项数据均居各省区市首位；脑机接口专利申请量360项，居全国第二；专利转让方面，中国科学院深圳先进技术研究院、华南理工大学分别位列全国第一、第三位。
On October 21, the Guangdong-Hong Kong-Macao Greater Bay Area International Brain-Computer Interface Industry Innovation Conference and the 6th Brain Science Frontier and Industry Conference were held in Guangming District, Shenzhen, where the "Guangdong Province Brain-Computer Interface Industry Development White Paper (2026 Edition)" was released. The white paper shows Guangdong's BCI industry has reached the national first tier, with over 100 key enterprises holding BCI product registration certificates or in-development products, ranking first nationally; 27 registered BCI-related clinical studies, accounting for 20.1% nationally, with 28 medical institutions establishing or planning BCI clinical research wards, all ranking first among provinces; 360 BCI patent applications, ranking second nationally; in patent transfers, the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and South China University of Technology rank first and third nationally respectively.
今年3月，脑机接口首次写入政府工作报告，与量子科技、6G等并列为六大未来产业之一。6月，《广东省脑机接口科技与产业协同发展行动计划（2026-2030年）》印发，明确短期攻坚、中期拓展、远期跃升三步走部署；7月，粤港澳大湾区脑机接口产业创新联盟在广州成立，首批成员达124家，覆盖基础研究、核心器件、算法软件、系统集成、临床应用、科技金融等全链条。白皮书分析，广东已形成广深双核错位、珠三角配套协同、粤东西北应用拓展的产业格局，坚定走非侵入式为主战场、侵入式跟踪布局的差异化发展路径。
In March this year, BCI was first written into the government work report, listed alongside quantum technology and 6G as one of six major future industries. In June, the "Guangdong Province BCI Science and Technology and Industry Coordinated Development Action Plan (2026-2030)" was issued, clarifying a three-step deployment of short-term breakthrough, medium-term expansion, and long-term leap; in July, the Guangdong-Hong Kong-Macao Greater Bay Area BCI Industry Innovation Alliance was established in Guangzhou with 124 first-batch members covering the full chain of basic research, core devices, algorithm software, system integration, clinical applications, and technology finance. The white paper analyzes Guangdong has formed an industrial pattern of "Guangzhou-Shenzhen dual-core staggered positioning, Pearl River Delta supporting coordination, and eastern/western/northern Guangdong application expansion," firmly taking the differentiated development path of "non-invasive as main battlefield, invasive tracking."
优先发展非侵入式脑机接口，是因其使用门槛低、场景适配性广、工程迭代快，可率先在康复训练、神经功能评估、状态监测、健康管理等领域实现规模化应用。广东在非侵入式领域已形成扎实的产业基础与技术储备，拥有相关企业88家。例如，华南脑控有多款非侵入式脑机接口产品上市销售，覆盖养老助残、心理健康、军事航天等领域。《行动计划》明确，到2030年打造10款以上非侵入式脑机接口爆款产品。侵入式及半侵入式技术是脑机接口领域的长期技术制高点，需围绕柔性电极、专用芯片、封装与无线传输、神经外科手术路径、长期生物安全性等核心方向持续攻关。广东在侵入式领域亦取得多项标志性进展。临床端，南方医科大学珠江医院完成华南地区首例侵入式脑机接口植入手术；企业技术端，深圳微灵医疗研发出临床级硬膜下全植入脑机系统，其高密度柔性电极阵列可将临床植入损伤降低80%。
Prioritizing non-invasive BCI is because of its low usage threshold, broad scenario adaptability, and fast engineering iteration, enabling scaled applications first in rehabilitation training, neural function assessment, state monitoring, and health management. Guangdong has formed solid industrial foundation and technical reserves in the non-invasive field, with 88 related enterprises. For example, Huanan Brain-Computer has multiple non-invasive BCI products on sale, covering elderly assistance, mental health, military aerospace, and other fields. The Action Plan specifies building over 10 non-invasive BCI hit products by 2030. Invasive and semi-invasive technologies are the long-term technical high ground in BCI, requiring continuous breakthroughs around flexible electrodes, dedicated chips, packaging and wireless transmission, neurosurgical pathways, and long-term biosafety. Guangdong has also achieved multiple landmark advances in the invasive field. On the clinical side, Zhujiang Hospital of Southern Medical University completed South China's first invasive BCI implantation surgery; on the enterprise technology side, Shenzhen Weiling Medical developed a clinical-grade subdural fully implantable BCI system, whose high-density flexible electrode array can reduce clinical implantation damage by 80%.
这份白皮书和前面讨论的武汉脑机接口产业布局可以对照着看。前面讨论过武汉布局侵入式、半侵入式和非侵入式3条主要路线，技术谱系完备，拥有重点企业20多家，整体发展水平位居全国第一方阵，也讨论过武汉光谷国际脑机接口创新中心把上下游企业塞进一栋楼。广东和武汉的路径有明显差异。武汉是三条路线并行，广东是明确以非侵入式为主战场、侵入式跟踪布局。这个差异背后是产业禀赋的不同。广东有强大的消费电子和医疗器械制造基础，非侵入式脑机接口产品化门槛相对低、迭代快，更适合广东的制造和供应链优势。武汉有同济、协和等头部医院的临床资源，三条路线都有临床案例，更适合做技术谱系完整的布局。两种路径没有高下之分，都是根据本地产业基础做出的选择。
This white paper can be compared with the previously discussed Wuhan BCI industry布局. Earlier we discussed Wuhan布局 three main routes—invasive, semi-invasive, and non-invasive—with a complete technical spectrum, over 20 key enterprises, and overall development level in the national first tier, and Wuhan Optics Valley International BCI Innovation Center packing upstream and downstream enterprises into one building. Guangdong and Wuhan's paths differ明显. Wuhan runs three routes in parallel; Guangdong explicitly takes non-invasive as the main battlefield with invasive tracking布局. This difference reflects different industrial endowments. Guangdong has strong consumer electronics and medical device manufacturing foundations; non-invasive BCI productization thresholds are relatively low and iteration fast, better suiting Guangdong's manufacturing and supply chain advantages. Wuhan has clinical resources from leading hospitals including Tongji and Union, with clinical cases across all three routes, better suiting a complete technical spectrum. Neither path is superior—both are choices based on local industrial foundations.
